

Porto Thyroid Meeting Papillary Carcinoma - Is Less More?

May 13, 2023

Fundação Dr. Cupertino de Miranda - Porto

Incidence of malignant thyroid tumors is increasing in the Western world. More than 80% of these are papillary carcinomas which usually have an excellent prognosis. In recent years important changes have emerged in this context. From ultrasound stratification to histological classification, from parenchymal sparing surgery to active surveillance strategy, from ablative therapy to endoscopic surgery, there are many novelties in the diagnosis and treatment of these tumors.

The big question today is how to distinguish aggressive papillary carcinomas from the majority that are indolent and easily treatable?

What is the prognosis of those that recur? is it different from those initially treated aggressively?

This is a meeting with experts from all over Europe where we will try to present new trends and answer these important questions.

Meeting attendees: General Surgery, Endocrinology, Otorhinolaryngology Physicians and Residents | Medical Students

Programme

08h00 Registration

08h30 Diagnosis

FNAC and Core-Needle Biopsy Genetic and MiRNA deregulation Image Sentinel node Risk classification and extent of surgery

Live Surgery (minimal edited videos) | 60' TA/TOETVA/Robotic

11h30 Minimally invasive strategies

Watch and wait Thermo ablation for primary disease Endoscopic trans cutaneous approach Endoscopic trans oral approach Robotic radical surgery

13h30 Lunch time

14h30 Morbidity

Neuro monitoring RLN lesion and rehabilitation Vascular fluorescent assessment for parathyroids Permanent hypoparathyroidis Trachea lesions Voice and swallowing optimization

Live (minimal edited videos) | 30'

in the peri-operative period

Percutaneous techniques - RF/MicroWaves/Alcohol

17h30 Advanced disease

Alcohol, Laser, MW, RF for cervical recurrence

Cervical re-operation

lodo therapy - how to calculate the dose

Raising tireoglobulin without detected disease

Extracervical recurrent disease - surgery vs iodotherapy vs immunotherapy

Course directors:

Jaime Vilaça (Hospital da Luz/Universidade do Minho) | Oscar Vidal (Hospital Clínic/Universitat de Barcelona)

Organizing committee:

Carlos Serra (Hospital do SAMS - Lisboa) | Susana Graça (Centro Hospitalar Vila Nova de Gaia e Espinho) Carlos Eduardo Costa Almeida (Instituto Português de Oncologia de Coimbra)

Hospital da Luz Learning Health • hospitaldaluz.pt/learninghealth T.: +351 217 104 544 (chamada para a rede fixa nacional) • E.: learninghealth@up.events Hospital da Luz Arrábida • hospitaldaluz.pt/arrabida Praceta Henrique Moreira, 150 • 4400-346 Vila Nova de Gaia • Portugal



